| Market Cap | 36.28M |
| Revenue (ttm) | 2.89M |
| Net Income (ttm) | -28.16M |
| Shares Out | n/a |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,170 |
| Average Volume | 33,725 |
| Open | 0.1602 |
| Previous Close | 0.1900 |
| Day's Range | 0.1602 - 0.2200 |
| 52-Week Range | 0.1200 - 0.6800 |
| Beta | n/a |
| RSI | 47.06 |
| Earnings Date | Jun 16, 2025 |
About Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, pa... [Read more]
Financial Performance
In 2024, Renalytix's revenue was $2.29 million, a decrease of -32.74% compared to the previous year's $3.40 million. Losses were -$33.46 million, -26.64% less than in 2023.
Financial StatementsNews
Renalytix Plc (RNLXY) Q2 2025 Earnings Call Transcript
Renalytix Plc (OTC:RNLXY) Q2 2025 Earnings Conference Call March 18, 2025 10:00 AM ET Company Participants Julian Baines - Executive Chairman Fergus Fleming - Chief Technology Officer James McCullough...
Renalytix plc Reports Financial Results for First Quarter of Fiscal Year 2025
LONDON and NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management...